Lyn M. Moir

University of Sydney — Australia

Medicine · Health Sciences

22h-index1.4kcitations57works0.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Asthma and respiratory diseases(22), Tuberous Sclerosis Complex Research(12), Cell Adhesion Molecules Research(7), Inhalation and Respiratory Drug Delivery(6), RNA Interference and Gene Delivery(5)

Publications57 total

Prospective nanoparticle treatments for lymphangioleiomyomatosis
Expert Opinion on Drug Delivery·2022· 1 cited
Properties of Rapamycin Solid Lipid Nanoparticles for Lymphatic Access Through The Lungs & Part II: The Effect of Nanoparticle Charge
Nanomedicine·2020· 14 cited
Properties of Rapamycin Solid Lipid Nanoparticles for Lymphatic Access Through The Lungs & Part I: The Effect of Size
Nanomedicine·2020· 7 cited
Delivery of pDNA to lung epithelial cells using PLGA nanoparticles formulated with a cell-penetrating peptide: understanding the intracellular fate
Drug Development and Industrial Pharmacy·2020· 26 cited
The effects of charge on inhaled rapamycin solid lipid nanoparticles for lymphatic targeting
2020
The effects of inhaled Rapamycin solid lipid particle size on transport across lung epithelial cells
Journal of Glycomics & Lipidomics·2020Open Access
Inhaled rapamycin solid lipid nano particles for the treatment of Lymphangioleiomyomatosis
European Journal of Pharmaceutical Sciences·2019· 28 cited
Nanotoxicologic Effects of PLGA Nanoparticles Formulated with a Cell-Penetrating Peptide: Searching for a Safe pDNA Delivery System for the Lungs
Pharmaceutics·2019· 42 citedOpen Access
Delivery of pDNA Polyplexes to Bronchial and Alveolar Epithelial Cells Using a Mesh Nebulizer
Pharmaceutical Research·2018· 8 cited
Delivery of pDNA to alveolar epithelial cells via nebulization
2017
Using a cell-penetrating peptide to enhance pDNA uptake in lung epithelial cells
2016
Lymphangioleiomyomatosis: Current understanding and potential treatments
Pharmacology & Therapeutics·2015· 45 cited
Doxycycline reduces the migration of tuberous sclerosis complex‐2 null cells ‐ effects on RhoA‐<scp>GTP</scp>ase and focal adhesion kinase
Journal of Cellular and Molecular Medicine·2015· 9 citedOpen Access
Inhalable tranexamic acid for haemoptysis treatment
European Journal of Pharmaceutics and Biopharmaceutics·2015· 22 cited
Novel drug targets for asthma and COPD: Lessons learned from in vitro and in vivo models
Pulmonary Pharmacology & Therapeutics·2014· 36 cited
LF-15 &amp; T7, Synthetic Peptides Derived from Tumstatin, Attenuate Aspects of Airway Remodelling in a Murine Model of Chronic OVA-Induced Allergic Airway Disease
PLoS ONE·2014· 12 citedOpen Access
Therapeutic strategies in lymphangioleiomyomatosis (LAM)
Respiratory Investigation·2013Open Access
Combination therapy may be beneficial for the treatment of lymphangioleiomyomatosis
2013
Lamstatin – a novel inhibitor of lymphangiogenesis derived from collagen <scp>IV</scp>
Journal of Cellular and Molecular Medicine·2012· 26 citedOpen Access
Emerging airway smooth muscle targets to treat asthma
Pulmonary Pharmacology & Therapeutics·2012· 33 cited
page 1 of 3Next →

Frequent Co-authors

Janette K. Burgess(26), Judith L. Black(26), Brian G. Oliver(23), Qi Ge(10), Paul M. Young(10), Daniela Traini(10), Thomas Trian(6), Stuart J. Hirst(5), Larissa Gomes dos Reis(5), Maree Svolos(5), Emelie Landh(5), Hui Xin Ong(5), Markus Weckmann(4), Rima Jaber(4), Norbert Windhab(4), Vera P. Krymskaya(4), Ho Yin Ng(4), Clare G. McVicker(3), Kyoko Niimi(3), Sarah Boustany(3)